NCT00372528

An Open-Label Study Of Pregabalin In Subjects With Refractory Partial Seizures

An Open-Label, Multi-Center, Add-On Study Of Pregabalin (LYRICA) In Subjects With Refractory Partial Seizures Who Have Completed Studies 1008-010, 1008-035, 1008-114 Or 1008-164

• Status: Terminated
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this trial is to allow continued access to pregabalin to Canadian subjects who participated in global pregabalin epilepsy studies 1008-010; 1008-035; 1008-114 and 1008-164 and to continue to study the long term safety of pregabalin administered as adjunctive therapy at dosages from 150 mg/day to 600 mg/day in Canadian subjects with refractory partial seizures.

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	pregabalin (LYRICA)	150 mg up to a maximum of 600 mg per day bid or tid as required

Timeline

• Start date: 2007-03-01
• Primary completion: 2011-10-01
• Completion: 2011-10-01
• First posted: 2006-09-07
• Last updated: 2021-01-26
• Results posted: 2012-10-23

Locations

5 sites across 1 country: Canada